[go: up one dir, main page]

US20020058694A1 - Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents - Google Patents

Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents Download PDF

Info

Publication number
US20020058694A1
US20020058694A1 US09/986,310 US98631001A US2002058694A1 US 20020058694 A1 US20020058694 A1 US 20020058694A1 US 98631001 A US98631001 A US 98631001A US 2002058694 A1 US2002058694 A1 US 2002058694A1
Authority
US
United States
Prior art keywords
oxygen
phenyl
aminocarbonylamino
alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/986,310
Inventor
Ernesto Menta
Nicoletta Pescalli
Marco Conti
Gerd Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Priority to US09/986,310 priority Critical patent/US20020058694A1/en
Publication of US20020058694A1 publication Critical patent/US20020058694A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones which were found to possess a marked antitumor activity, especially against colon cancers.
  • Colo-rectal carcinoma is one of the most common tumors in industrialized world; with an incidence of approximately 421,000 new cases/year world-wide, it is second only to lung and mammary tumors in causing death.
  • the rate of patients curable with surgery only is approximately 45-50%.
  • the others may be treated with combination chemotherapy which allows to a complete remission rate of no more than 5%.
  • Colo-rectal tumors are usually refractory or poorly sensitive to available chemotherapy and the only agent which provides some responses against this cancer is 5-Fluorouracil.
  • A is oxygen or sulfur
  • X is oxygen or sulfur
  • R1 and R2 are independently hydrogen or an alkyl group with from 1 to 6 carbon atoms;
  • R is selected from: (C 1 -C 10 )alkyl, (C 3 -C 7 )cycloalkyl, naphthyl, phenyl, phenyl substituted by from 1 to 3 groups selected from: (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkylsulphinyl, (C 1 -C 4 )alkylsulphonyl, (C 1 -C 4 )hydroxyalkyl, (C 1 -C 4 )alkyl; chlorine, bromine, iodine or fluorine; (C 1 -C 4 )perfluoroalkyl; hydroxy; (C 1 -C 4 )alkoxy; amino; mono- or di-(C 1 -C 4 )alkylamino; aminosulphonyl; (C 1 -C 4 )alkylsulphonamido; phenyl- or tolylsulphonamido; carboxy
  • R is a heterocycle, it is preferably selected from pyridine, pyrrole, thiazole, thiophene, furane, imidazole, pyrazine, pyrimidine, quinoline, isoquinoline, indole, 3,4-methylenedioxyphenyl, piperazine, piperidine, morpholine and pyrrolidine.
  • Preferred compounds of formula (I) are those in which X is oxygen, R1 and R2 are hydrogen and R is a substituted phenyl group.
  • a further object of the present invention is to provide processes for the preparation of the compounds of formula (I).
  • a still another object of the present invention are pharmaceutical formulations containing a pharmaceutically effective dosage of one or more compounds of formula (I) in admixture with pharmaceutically acceptable excipients.
  • R1 and R2 have the above meanings, Hal is bromine or chlorine and Y is a lower alkyl group, with an urea or thiourea of formula (III)
  • R and X have the above meanings, preferably in a solvent and at temperatures ranging from room temperature to the boiling temperature of the solvent, as described in U.S.-Re 27,894, which is herein incorporated by reference.
  • An alternative process comprises the reaction of a 4-amino-2(5H)furanone of formula (IV):
  • reaction comprises the formation of a sodium salt of intermediate of formula (IV) (by reaction with sodium hydride at 40-50° C.), followed by the condensation reaction with the compound of formula fi) at about 50° C.
  • the use, in the first step, of a different strong base at temperatures ranging from 0° C. to 100° C. can be also advantageously provided.
  • a still alternative process is to react intermediates of formula (IV) with 1,1′-carbonyl diimidazole or 1,1′-thiocarbonyl diimidazole, respectively, followed by reaction with an amine of formula (VI) R—NH 2 .
  • A is oxygen or sulfur and R 1 and R 2 have the above-mentioned meanings, with an urea or thiourea of formula (III), in solution at reflux or at 50 to 150° C., preferably at 80 to 120° C., without solvent and, if necessary to achieve a clear melt, a small amount of a high boiling solvent e.g. toluene, xylene, dioxane, dimethylformamide, nitromethane or n-butanol.
  • a high boiling solvent e.g. toluene, xylene, dioxane, dimethylformamide, nitromethane or n-butanol.
  • the compounds of formula (VII) can be prepared by heating the halogen-acetoacetates of formula (II) in a solvent.
  • the compounds of the invention were tested against three human colon tumor cell lines (HT 29, HCT 116 and LoVo). After 144 hours of incubation of the cells with the compound to be tested, the cytotoxicity is evaluated using the MTT assay (Mosman, T. “Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assay”; J. Immunol. Methods, (1983), 65, 66; Green, L. M., “Rapid Colorimetric Assay for Cell Viability; Application to the Quantitation of Cytotoxic and Growth Inhibitory Lymphokines”, J. Immunol. Methods, (1984), 70, 257-268). The results are expressed as IC 50 (Tg/ml), that it the concentration of the tested compound which causes the death of 50% of cell population.
  • the compounds of the present invention can be administered in doses ranging from 0.01 mg to 0.4 g per kilogram of body weight daily.
  • a preferred dosage regimen to obtain best results is that which provides for the use from about 1 mg to about 50 mg per kilogram of body weight daily, employing unitary doses so that to administer in 24 hours from about 70 mg to about 3.5 g of the active compound to a patient having approximately 70 kg of body weight.
  • Such a dosage regimen may be adjusted to achieve the best therapeutical effect.
  • doses may be administered taking into account the therapeutical situation of the patient.
  • the active compound may be administered by oral, intravenous, intramuscular or subcutaneous route.
  • compositions of the present invention contain therapeutical effective amounts of at least one compound of the invention in admixture with pharmaceutically compatible excipients.
  • Oral compositions will generally include an inert diluent or an edible carrier. They can be included in gelatin capsules or compressed into tablets. Other oral administration forms are capsules, pills, elixirs, suspensions or syrups.
  • the tablets, pills, capsules and similar compositions can contain the following ingredients (in addition to the active compound): a binder such as microcrystalline cellulose, tragacanth or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, primogel, maize starch and the like; a lubricant such as magnesium stearate; a fluidifier such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharine or a flavoring agent such as mint flavor, methyl salicylate or orange flavor.
  • a binder such as microcrystalline cellulose, tragacanth or gelatin
  • an excipient such as starch or lactose
  • a disintegrating agent such as alginic acid, primogel, maize starch and the like
  • a lubricant such as magnesium stearate
  • a fluidifier such as colloidal silicon dioxide
  • a sweetening agent such as sucrose or saccharine or a flavoring agent
  • the active ingredient can be included in solutions or suspensions, which can comprise in addition the following components: a sterile diluent such as water for injections, saline solution, oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminotetracetic acid; buffers such as acetates, citrates or phosphates and agents for adjusting the tonicity of the solution, such as sodium chloride or dextrose.
  • the parenteral preparation can be included in ampoules, mono-dose syringes, glass or plastic vials.
  • Elem. Anal. (% calcd/found): C 60.55/59.46; H 4.62/4.67; N 12.84/12.96.
  • the crude product is then suspended under reflux in 20 ml of dioxane for 45 minutes, then the suspension is allowed to return to room temperature and the solid is recovered by filtration and washed with dioxane (1 ml) and then with diethyl ether (2 ml). After drying overnight under vacuum at 40° C., 1.1 g of the product are obtained, which still contains some impurities.
  • TLC sica gel, eluant methylene chloride/methanol 9:1; UV detection at 254 nm
  • single spot at R f 0.39.
  • This material is suspended in 10 ml of 1 N potassium hydrogencarbonate for 30 minutes, then it is recovered by filtration and dried under vacuum at 40° C. to give 0.7 g of a residue which is dissolved in dimethylformamide (1.1 ml) at 100° C. Upon cooling to room temperature a dense precipitate is obtained, which is diluted with 11 ml of diethyl ether. After stirring for 4 hours, the white solid is recovered by filtration and dried overnight under vacuum at 80° C., to give 0.49 g of the pure product, m.p. 162-164° C.
  • TLC sica gel, eluant methylene chloride/methanol 89.11; UV detection at 254 nm
  • single spot at R f 0.45.
  • the products were characterized by mass spectrometry (atmospheric pressure chemical ionization (APCI)) and tlc using silica gel and LAE (hexane/acetone/acetic acid 60:40:1) or MAE (dichloromethane/acetone/acetic acid 80:20:3) as eluant.
  • APCI atmospheric pressure chemical ionization
  • nn 4-[N-(tert-butyl)aminothiocarbonylamino]-2(5H)-furanone;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Subject of the present invention are compounds of general formula (I), wherein A is oxygen or sulfur; X is oxygen or sulfur, R1 and R2 are independently hydrogen or an alkyl group with from 1 to 6 carbon atoms; R is selected from alkyl, cycloalkyl, alkylsulphinyl, alkylsulphonyl, hydroxyalkyl, napthtyl, phenyl group which can be unsubsituted or substituted; or R is a 5- or 6-membered heterocycle containing from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, which can be optionally benzocondensed, the pure steroisomers or mixtures thereof as well as salts thereof with pharmaceutically acceptable acids or bases, for the use as medicaments, in particular as antitumor agents.
Figure US20020058694A1-20020516-C00001

Description

  • The present invention relates to ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones which were found to possess a marked antitumor activity, especially against colon cancers. [0001]
    • BACKGROUND OF THE INVENTION
  • Colo-rectal carcinoma is one of the most common tumors in industrialized world; with an incidence of approximately 421,000 new cases/year world-wide, it is second only to lung and mammary tumors in causing death. The rate of patients curable with surgery only is approximately 45-50%. The others may be treated with combination chemotherapy which allows to a complete remission rate of no more than 5%. [0002]
  • Colo-rectal tumors are usually refractory or poorly sensitive to available chemotherapy and the only agent which provides some responses against this cancer is 5-Fluorouracil. [0003]
  • So far no therapeutic alternatives exist after the failure of the first-line combination chemotherapy essentially based on 5-FU. [0004]
  • Despite many new investigational agents are undergoing preclinical and clinical studies against colorectal cancer, it is generally believed that only compounds with innovative structures and possible new mechanisms of action may be successful against this highly refractory tumor hystotype. [0005]
  • Therefore the search for new active drugs in this indication still represents one of the most interesting and attractive field in oncology. [0006]
  • We have now discovered a new class of compounds, namely 4-ureido and thioureido 2(5H)-furanones, respectively 2(5H)-thiophenones, which possesses a marked antitumor activity, especially against colon cancers. [0007]
  • Phenylureido furanones have been already described having activity as defoliants (Reissue U.S. Pat. No. 27,894), as herbicides (JP 63-174983) or in Bull. Chem. Soc. Jpn. Vol. 60, 2139ff as intermediates. However, no pharmaceutical activity, especially antitumour activity, has been reported in these documents. Only DE-A-25 16 555 describes 1-tert.alkyl-3-(substituted furyl)-urea-derivatives with an antihypertensive activity. [0008]
    • DESCRIPTION OF THE INVENTION
  • Object of the present invention are compounds of the General formula (I): [0009]
    Figure US20020058694A1-20020516-C00002
  • wherein: [0010]
  • A is oxygen or sulfur; [0011]
  • X is oxygen or sulfur, [0012]
  • R1 and R2 are independently hydrogen or an alkyl group with from 1 to 6 carbon atoms; [0013]
  • R is selected from: (C[0014] 1-C10)alkyl, (C3-C7)cycloalkyl, naphthyl, phenyl, phenyl substituted by from 1 to 3 groups selected from: (C1-C4)alkylthio, (C1-C4)alkylsulphinyl, (C1-C4)alkylsulphonyl, (C1-C4)hydroxyalkyl, (C1-C4)alkyl; chlorine, bromine, iodine or fluorine; (C1-C4)perfluoroalkyl; hydroxy; (C1-C4)alkoxy; amino; mono- or di-(C1-C4)alkylamino; aminosulphonyl; (C1-C4)alkylsulphonamido; phenyl- or tolylsulphonamido; carboxy; (C1-C4)alkoxycarbonyl; amidocarbonyl or (C1-C4)alkylamidocarbonyl; carboxaldehyde; (C1-C4)alkylcarbonyl; nitro; phenylthio; cyanomethyl, and optionally substituted phenyloxy or optionally substituted phenyl-(C1-C4)-alkyl or R is a 5- or 6-membered aromatic or non-aromatic heterocycle containing from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, which can be optionally benzocondensed, with the proviso, that when A is oxygen and X is oxygen, R is not (C1-C10) alkyl. the pure stereoisomers or mixtures thereof as well as salts thereof with pharmaceutically acceptable acids or bases, for the use as medicaments, in particular as antitumor agents. When R is a heterocycle, it is preferably selected from pyridine, pyrrole, thiazole, thiophene, furane, imidazole, pyrazine, pyrimidine, quinoline, isoquinoline, indole, 3,4-methylenedioxyphenyl, piperazine, piperidine, morpholine and pyrrolidine.
  • The compounds in which R is an unsubstituted phenyl group or (C[0015] 1-C10) alkyl and X is oxygen are known (U.S.-Re 27,894; JP 63-174983; DE-A-2 516 555 and Bull. Chem. Soc. Jpn. Vol. 60, 2139ff). Therefore, another object of the present invention are new compounds of formula (I), with the proviso that, when X is oxygen, R is not an unsubstituted phenyl group or C1-C10 (alkyl).
  • Preferred compounds of formula (I) are those in which X is oxygen, R1 and R2 are hydrogen and R is a substituted phenyl group. [0016]
  • Particularly preferred compounds of formula (I) are: [0017]
  • 4-[N-(4-chlorophenyl)aminocarbonylamino]-2(5H)-furanone; [0018]
  • 4-[N-(4-ethyl-3-chlorophenyl)aminocarbonylamino]-2(5H)-furanone. [0019]
  • A further object of the present invention is to provide processes for the preparation of the compounds of formula (I). [0020]
  • A still another object of the present invention are pharmaceutical formulations containing a pharmaceutically effective dosage of one or more compounds of formula (I) in admixture with pharmaceutically acceptable excipients. [0021]
    • PREPARATION OF THE COMPOUNDS OF THE INVENTION
  • The compounds of formula (I) wherein A is oxygen, can be prepared by reacting bromo- or chloro-acetoacetate of formula (II): [0022]
    Figure US20020058694A1-20020516-C00003
  • wherein R1 and R2 have the above meanings, Hal is bromine or chlorine and Y is a lower alkyl group, with an urea or thiourea of formula (III) [0023]
    Figure US20020058694A1-20020516-C00004
  • wherein R and X have the above meanings, preferably in a solvent and at temperatures ranging from room temperature to the boiling temperature of the solvent, as described in U.S.-Re 27,894, which is herein incorporated by reference. [0024]
  • The preparation of intermediates of formula (II) and (III), which are mainly commercial and widely known products, is also described in U.S.-Re 27,894. [0025]
  • An alternative process comprises the reaction of a 4-amino-2(5H)furanone of formula (IV): [0026]
    Figure US20020058694A1-20020516-C00005
  • wherein A is oxygen or sulfur and R[0027] 1 and R2 have the above-mentioned meanings, with an isocyanate or an isothiocyanate of formula (V):
  • R—N═C═X   (V)
  • as described in JP 63-174983, which is herein incorporated by reference. The reaction comprises the formation of a sodium salt of intermediate of formula (IV) (by reaction with sodium hydride at 40-50° C.), followed by the condensation reaction with the compound of formula fi) at about 50° C. The use, in the first step, of a different strong base at temperatures ranging from 0° C. to 100° C. can be also advantageously provided. A still alternative process is to react intermediates of formula (IV) with 1,1′-carbonyl diimidazole or 1,1′-thiocarbonyl diimidazole, respectively, followed by reaction with an amine of formula (VI) R—NH[0028] 2.
  • Another alternative process is to react a compound of formula (VII): [0029]
    Figure US20020058694A1-20020516-C00006
  • wherein A is oxygen or sulfur and R[0030] 1 and R2 have the above-mentioned meanings, with an urea or thiourea of formula (III), in solution at reflux or at 50 to 150° C., preferably at 80 to 120° C., without solvent and, if necessary to achieve a clear melt, a small amount of a high boiling solvent e.g. toluene, xylene, dioxane, dimethylformamide, nitromethane or n-butanol.
  • The synthesis of the 4-aminofuranones of formula (IV) is described in Bull. Chem. Soc. Jpn., 60, 2139-50 (1987), which is herein incorporated by reference. When R1 and R2 are both hydrogen, the compound of formula (IV) can be obtained by fusion of the corresponding compound of formula (VII) with ammonium acetate. [0031]
  • The compounds of formula (V) and (VI) are commercial and known compounds, which can be prepared according to methods which are part of the general knowledge of the chemist. [0032]
  • The compounds of formula (VII) can be prepared by heating the halogen-acetoacetates of formula (II) in a solvent. [0033]
    • Biological Activity of the Compounds of the Invention
  • The compounds of the invention were tested against three human colon tumor cell lines (HT 29, HCT 116 and LoVo). After 144 hours of incubation of the cells with the compound to be tested, the cytotoxicity is evaluated using the MTT assay (Mosman, T. “Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assay”; J. Immunol. Methods, (1983), 65, 66; Green, L. M., “Rapid Colorimetric Assay for Cell Viability; Application to the Quantitation of Cytotoxic and Growth Inhibitory Lymphokines”, J. Immunol. Methods, (1984), 70, 257-268). The results are expressed as IC[0034] 50 (Tg/ml), that it the concentration of the tested compound which causes the death of 50% of cell population.
  • The data for two representative compounds of the invention are shown in table 1. [0035]
    TABLE I
    Cytotoxic activity of the compounds of the invention against human colon
    cancer cell lines HT 29, HCT 116 and LoVo.
    HT 29 HCT 116 LoVo
    structure example IC50 (Tg/ml) IC50 (Tg/ml) IC50 (Tg/ml)
    Figure US20020058694A1-20020516-C00007
         		3 0.003 <0.01 0.034
    Figure US20020058694A1-20020516-C00008
         		2 0.032 0.034 0.01
  • From the above data it appears that the compounds of the invention are endowed with a marked activity against the colon cancers. [0036]
  • The compounds of the present invention can be administered in doses ranging from 0.01 mg to 0.4 g per kilogram of body weight daily. A preferred dosage regimen to obtain best results is that which provides for the use from about 1 mg to about 50 mg per kilogram of body weight daily, employing unitary doses so that to administer in 24 hours from about 70 mg to about 3.5 g of the active compound to a patient having approximately 70 kg of body weight. Such a dosage regimen may be adjusted to achieve the best therapeutical effect. For example, doses may be administered taking into account the therapeutical situation of the patient. The active compound may be administered by oral, intravenous, intramuscular or subcutaneous route. [0037]
  • The pharmaceutical compositions of the present invention contain therapeutical effective amounts of at least one compound of the invention in admixture with pharmaceutically compatible excipients. [0038]
  • Oral compositions will generally include an inert diluent or an edible carrier. They can be included in gelatin capsules or compressed into tablets. Other oral administration forms are capsules, pills, elixirs, suspensions or syrups. [0039]
  • The tablets, pills, capsules and similar compositions can contain the following ingredients (in addition to the active compound): a binder such as microcrystalline cellulose, tragacanth or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, primogel, maize starch and the like; a lubricant such as magnesium stearate; a fluidifier such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharine or a flavoring agent such as mint flavor, methyl salicylate or orange flavor. When the composition selected is in form of capsules, it can contain in addition a liquid carrier such as a fat oil. Other compositions can contain various material which change the physical form thereof, for example coating agents (for tablets and pills) such as sugar or shellac. The material used in the preparation of the compositions should be pharmaceutically pure and non toxic at the used dosages. [0040]
  • For the preparation of pharmaceutical compositions for the parenteral administration, the active ingredient can be included in solutions or suspensions, which can comprise in addition the following components: a sterile diluent such as water for injections, saline solution, oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminotetracetic acid; buffers such as acetates, citrates or phosphates and agents for adjusting the tonicity of the solution, such as sodium chloride or dextrose. The parenteral preparation can be included in ampoules, mono-dose syringes, glass or plastic vials. [0041]
  • The following examples further illustrate the invention.[0042]
    • EXAMPLE 1 4[N-(phenyl)aminocarbonylamino]-2(5H)-furanone
  • A mixture of N-phenylurea (1.36 g) and 2,4(3H,5H)-furanone (0.5 g) in 1 ml of ethanol is refluxed for 8 hours and the product which separates is recovered by filtration, to give, after recrystallization from dioxane, 0.38 g of the product, m.p. 238-239° C. [0043]
  • TLC (silica gel, eluant methylene chloride/methanol 9:1; UV detection at 254 nm): single spot at R[0044] f=0.44.
  • Elem. Anal. (% calcd/found): C 60.55/59.46; H 4.62/4.67; N 12.84/12.96. [0045]
    • EXAMPLE 2 4-[N-(4-chlorophenyl)aminocarbonylamino]-2(5H)-furanone
  • To a magnetically stirred suspension of 4-chlorophenylurea (2 g) in dioxane (4 ml), ethyl 4-chloroacetoacetate (1.63 ml) are added and the suspension is heated to reflux for two hours, then kept at room temperature overnight. The yellowish gray precipitate is recovered by filtration and washed with the mother liquor, with methanol (2×1 ml) and finally with diethyl ether (2 ml). After drying under vacuum at 40° C. overnight, 1.34 g of crude product were obtained. The crude product is then suspended under reflux in 20 ml of dioxane for 45 minutes, then the suspension is allowed to return to room temperature and the solid is recovered by filtration and washed with dioxane (1 ml) and then with diethyl ether (2 ml). After drying overnight under vacuum at 40° C., 1.1 g of the product are obtained, which still contains some impurities. [0046]
  • It is therefore dissolved in hot dimethylformamide (2.2 ml) and when a complete solution is obtained the heating bath is removed and the product reprecipitate in a short time. When the suspension reaches room temperature 11.2 ml of acetone are added and after stirring for 2 hours the solid is recovered by filtration and washed first with the mother liquor and then with acetone (2×3 ml). After drying under vacuum at 40° C. overnight, 0.73 g of off-white product are obtained, m.p.>254-256° C. [0047]
  • TLC (silica gel, eluant methylene chloride/methanol 9:1; UV detection at 254 nm): single spot at R[0048] f=0.39.
  • Elem. Anal. (% calcd/found): C 52.29/52.05; H 3.59/3.60; N 11.09/10.99; Cl 14.03/14.05. [0049]
    • EXAMPLE 3 4-[N-(4-ethyl-3-chlorophenyl)aminocarbonylamino)-2(5H)-furanone
  • To a magnetically stirred suspension of 3-chloro-4-ethylphenylurea (3.43 g) in 17 ml of dioxane, ethyl 4-chloroacetoacetate (2.4 ml) are added and the resulting dark solution is refluxed for 2 hours. The reaction mixture is then kept overnight at room temperature to give a precipitate which is recovered by filtration and washed with the mother liquor, with dioxane (2×2 ml) and with diethyl ether (2×2 ml). After drying under vacuum at 40° C. overnight 0.88 g of the crude product are obtained. [0050]
  • This material is suspended in 10 ml of 1 N potassium hydrogencarbonate for 30 minutes, then it is recovered by filtration and dried under vacuum at 40° C. to give 0.7 g of a residue which is dissolved in dimethylformamide (1.1 ml) at 100° C. Upon cooling to room temperature a dense precipitate is obtained, which is diluted with 11 ml of diethyl ether. After stirring for 4 hours, the white solid is recovered by filtration and dried overnight under vacuum at 80° C., to give 0.49 g of the pure product, m.p. 162-164° C. [0051]
  • TLC (silica gel, eluant methylene chloride/methanol 89.11; UV detection at 254 nm): single spot at R[0052] f=0.45.
  • Elem. Anal. (% calcd/found): C 55.62/55.36; H 4.67/4.68; N 9.98/9.87; Cl 12.63/12.83. [0053]
  • The following compounds were prepared using the method of example 3. [0054]
  • The products were characterized by mass spectrometry (atmospheric pressure chemical ionization (APCI)) and tlc using silica gel and LAE (hexane/acetone/acetic acid 60:40:1) or MAE (dichloromethane/acetone/acetic acid 80:20:3) as eluant. [0055]
  • a) 1-[2-(4-Chloro-phenyl)-1,1-dimethyl-ethyl]-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0056]
  • MS (APCI): [M+1]=309, [M−CO[0057] 2+H]=265
  • tlc: MAE, R[0058] f=0.53
  • b) 1-(2-Ethyl-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0059]
  • MS (APCI): [M+1]=247, [M−CO[0060] 2+H]=203
  • tlc: MAE, R[0061] f=0.48
  • c) 1-(2,3-Dimethyl-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0062]
  • MS (APCI): [M+1]=247, [M−CO[0063] 2+H]=203
  • tlc: MAE, R[0064] f=0.4
  • d) 1-(2,4-Dimethyl-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0065]
  • MS (APCI): [M+1]=247, [M−CO[0066] 2+H]=203
  • tlc: MAE, R[0067] f=0.36
  • e) 1-(4-Ethoxy-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0068]
  • MS (APCI): [M+1]=263, [M−CO[0069] 2+H]=219
  • tlc: MAE, R[0070] f=0.18
  • f) 1-(4-Fluoro-benzyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0071]
  • MS (APCI): [M+1]=251, [M−CO[0072] 2+H]=207
  • tlc: MAE, R[0073] f=0.13
  • g) 1-(5-Oxo-2,5-dihydro-furan-3-yl)-3-p-tolyl-urea [0074]
  • MS (APCI): [M+1]=233 [M−CO[0075] 2+H]=189
  • tlc: MAE, R[0076] f=0.23
  • h) 1-(5-Oxo-2,5-dihydro-furan-3-yl)-3-m-tolyl-urea [0077]
  • MS (APCI): [M+1]=233, [M−CO[0078] 2+H]=189
  • tlc: MAE, R[0079] f=0.23
  • i) 1-Cyclohexyl-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0080]
  • MS (APCI): [M+1]=225, [M−CO[0081] 2+H]=181
  • tlc: MAE, R[0082] f=0.45
  • j) 1-(4-Bromo-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0083]
  • MS (APCI): [M+1]=297, [M−CO[0084] 2+H]=253
  • tlc: MAE, R[0085] f=0.36
  • k) 1-(2-Fluoro-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0086]
  • MS (APCI): [M+1]=237, [M−CO[0087] 2+H=193
  • tlc: MAE, R[0088] f=0.54
  • l) 1-(5-Chloro-2-methyl-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0089]
  • MS (APCI): [M+1]=267, [M−CO[0090] 2+H]=223
  • tlc: MAE, R[0091] f=0.39
  • m) 1-(3-Chloro-benzyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0092]
  • MS (APCI): [M+1]=267, [M−CO[0093] 2+H]=223
  • tlc: MAE, R[0094] f=0.54
  • n) 1-(4-Chloro-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0095]
  • MS (APCI): [M+1]=253, [M−CO[0096] 2+H]=209
  • tlc: MAE, R[0097] f=0.4
    • EXAMPLE 4 4-[3-(5-Oxo-2,5-dihydro-furan-3-yl)-ureido]-benzoic Acid
  • A mixture of 180 mg 4-carboxy-phenyl-urea, 250 mg tetronic acid and 0.2 ml nitromethane was heated to 120° C. After 1 h at 120° C. the molten mixture is cooled to room temperature. Ethylacetate and water were added to the mixture. The organic phase was separated, washed with aqueous bicarbonate solution and water, dried and evaporated. The residue was triturated with ethylacetate and ether to yield 131 mg (51%) of the title product. [0098]
  • Tlc: (silica gel, isopropanol/butylacetate/water 10:6:2) R[0099] f=0.62
  • MS (APCI): [M+1]=263, [M−CO[0100] 2+1]219
    • EXAMPLE 5
  • The following compounds were prepared using the method of example 4. The products were characterized by mass spectrometry (atmospheric pressure chemical ionization) and tlc using silica gel and LAE (hexane:acetone/acetic acid 60:40:1), MAE (dichloromethane/acetone/acetic acid 80:20:3) or IBW (isopropanolybutyl acetate/water 10:6:2) as eluant. [0101]
  • a) 1-(3-Chloro-2-methyl-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0102]
  • MS (APCI): [M+1]=267, [M−CO[0103] 2÷H]=223
  • tlc: MAE, R[0104] f=0.38
  • b) 1-(5-Oxo-2,5-dihydro-furan-3-yl)-3-(3-trifluoromethyl-phenyl)-urea [0105]
  • MS (APCI): [M+1]=287, [M−CO[0106] 2+H]=243
  • t/c: MAE, R[0107] f=0.34
  • c) 1-(3-Bromo-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0108]
  • MS (APCI): [M+1]=297, [M−CO[0109] 2+H]=253
  • tlc: LAE, R[0110] f=0.27
  • d) 1-(2-Bromo-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0111]
  • MS (APCI): [M+1]=297, [M−CO[0112] 2+H]=253
  • tlc: LAE, R[0113] f=0.6
  • e) 1-Benzyl-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0114]
  • MS (APCI): [M+1]=233, [M−CO[0115] 2+H]=189
  • tlc: MAE, R[0116] f=0.16
  • f) 1-(5-Oxo-2,5-dihydro-furan-3-yl)-3 -o-tolyl-urea [0117]
  • MS (APCI): [M+1]=233, [M−CO[0118] 2+H]=189
  • tlc: MAE, R[0119] f=0.28
  • g) 1-(3-Methoxy-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0120]
  • MS (APCI): [M+1]=249, [M−CO[0121] 2+H]=205
  • tlc: MAE, R[0122] f=0.16
  • h) 1-(3-Chloro-4-methyl-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0123]
  • MS (APCI): [M+1]=267, [M−CO[0124] 2+H]=223
  • tlc: MAE, R[0125] f=0.3
  • i) 1-(2,3-Dichloro-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0126]
  • MS (APCI): [M+1]=288, [M−CO[0127] 2+H]=244
  • tlc: MAE, R[0128] f=0.4
  • j) 1-(3-Chloro-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0129]
  • MS (APCI): [M+1]=253, [M−CO[0130] 2+H]209
  • tlc: MAE, R[0131] f=0.24
  • k) 1-Naphthalen-1-yl-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0132]
  • MS (APCI): [M+1]=269, [M−CO[0133] 2+H]=225
  • tlc: MAE, R[0134] f=0.34
  • l) 1-[4-(3-Chloro-5-trifluoromethyl-pyridin-2-yloxy)-phenyl]-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0135]
  • MS (APCI): [M+1]=414, [M−CO[0136] 2+H]=370
  • tlc: LAE, R[0137] f=0.28
  • m) 1-(3,4-Dichloro-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0138]
  • MS (APCI): [M+1]=287, [M−CO[0139] 2+H]=243
  • tlc: MAE, R[0140] f=0.32
  • n) 1-(4-Acetyl-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0141]
  • MS (APCI): [M+1]=261, [M−CO[0142] 2+H]=217
  • tlc: IBW, R[0143] f=0.61
  • o) 1-(3-Acetyl-phenyl)-3-(5-oxo-2,5-dihydro-furan-3-yl)-urea [0144]
  • MS (APCI): [M+1]=261, [M−CO[0145] 2+H]=217
  • tlc: MAE, R[0146] f=0.68
    • EXAMPLE 6
  • According to the methods described in the previous examples, the following furanone derivatives are prepared: [0147]
  • a) 4-[N-(4-fluorophenyl)aminocarbonylamino]-2(5H)-furanone; [0148]
  • b) 4-[N-(4-chloro-3-ethylphenyl)aminocarbonylamino]-2(5H)-furanone; [0149]
  • c) 4-[N-(4-tert-butyl-3-fluorophenyl)aminocarbonylamino]-2(5H)-furanone; [0150]
  • d) 4-[N-(4-hydroxyphenyl)aminocarbonylamino]-2(5H)-furanone; [0151]
  • e) 4-[N-(4-aminophenyl)aminocarbonylamino]-2(5H)-furanone, [0152]
  • f) 4-[N-(4-diethylaminophenyl)aminocarbonylamino]-2(5H)-furanone; [0153]
  • g) 4-[N-(3-carboxyphenyl)aminocarbonylamino]-2(5H)-furanone; [0154]
  • h) 4-[N-(3-methoxycarbonylphenyl)aminocarbonylamino]-2(5H)-furanone; [0155]
  • i) 4-[N-(3-acetyl-4-fluorophenyl)aminocarbonylamino]-2(5H)-furanone; [0156]
  • j) 4-[N-(4-aminosulphonylphenyl)aminocarbonylamino]-2(5H)-furanone; [0157]
  • k) 4-[N-(4-methansulphonamidophenyl)aminocarbonylamino]-2(5H)-furanone; [0158]
  • l) 4-[N-(4-tolylsulphonamidophenyl)aminocarbonylamino]-2(5H)-furanone; [0159]
  • m) 4-[N-(2,4-difluorophenyl)aminocarbonylamino]-2(5H)-furanone; [0160]
  • n) 4-[N-(4-ethyl-2-chlorophenyl)aminocarbonylamino]-2(5H)-furanone; [0161]
  • o) 4-[N-(isopropyl)aminocarbonylamino]-2(5H)-furanone; [0162]
  • p) 4-[N-(tert-butyl)aminocarbonylamino]-2(5H)-furanone; [0163]
  • q) 4-[N-(octyl)aminiocarbonylamino]-2(5H)-furanone; [0164]
  • r) 4-[N-(cyclopropyl)aminocarbonylamino]-2(5H)-furanone; [0165]
  • s) 4-[N-(cyclohexyl)aminocarbonylamino]-2(5H)-furanone; [0166]
  • t) 4-[N-(2-pyridinyl)aminocarbonylamino]-2(5H)-furanone; [0167]
  • u) 4-[N-(1-isoquinolinylamnocarbonylamino]-2(5H)-furanone; [0168]
  • v) 4-[N-(3-quinolinyl)aminocarbonylamino]-2(5H)-furanone; [0169]
  • w) 4-[N-(3-indolyl)aminocarbonylamino]-2(5H)-furanone; [0170]
  • x) 4-[N-(2-thienyl)aminocarbonylamino]-2(5H)-furanone; [0171]
  • y) 4-[N-(2-pyrrolidinyl)aminocarbonylamino]-2(5H)- furanone; [0172]
  • z) 4-[N-(2-furanyl)aminocarbonylamino]-2(5H)-furanone, [0173]
  • aa) 4-[N-(2-imidazolyl)aminocarbonylamino]-2(5H)-furanone; [0174]
  • bb) 4-[N-(2-pyrrolyl)aminocarbonylamino]-2(5H)-furanone; [0175]
  • cc) 4-[N-(4-ethyl-3-chlorophenyl)aminocarbonylamino]-3-methyl-2(5H)-furanone; [0176]
  • dd) 4-[N-(4-ethyl-3-chlorophenyl)aminocarbonylamino]-3,5-dimethyl-2(5H)-furanone; [0177]
  • ee) 4-[N-(4-ethyl-3-chlorophenyl)aminocarbonylamino]-5-methyl-2(5H)-furanone; [0178]
  • ff) 4-[N-(4-chlorophonyl)aminocarbonylamino]-3-ethyl-2(5H)-furanone; [0179]
  • gg) 4-[N-(4-chlorophenyl)aminocarbonylamino]-5-propyl-2(5H)-furanone, [0180]
  • hh) 4-[N-(4-ethyl-3-chlorophenyl)aminothiocarbonylamino]-2(5H)-furanone; [0181]
  • ii) 4-[N-(4-chlorophenyl)aminothiocarbonylamino]-2(5H)-furanone; [0182]
  • jj) 4-[N-(4-fluorophenyl)aminothiocarbonylamino]-2(5H)-furanone; [0183]
  • kk) 4-[N-(4-chloro-3-ethylphenyl)aminothiocarbonylamino]-2(5H)-furanone; [0184]
  • ll) 4-[N-(4-tert-butyl-3-fluorophenyl)aminothiocarbonylamino]-2(5H)-furanone; [0185]
  • mm) 4-[N-(4-hydroxyphenyl)aminothiocarbonylamino]-2(5H)-furanone; [0186]
  • nn) 4-[N-(tert-butyl)aminothiocarbonylamino]-2(5H)-furanone; [0187]
  • oo) 4-[N-(octyl)aminothiocarbonylamino]-2(5H)-furanone; [0188]
  • pp) 4-[N-(cyclopropyl)aminothiocarbonylamino]-2(5H)-furanone; [0189]
  • qq) 4-[N-(cyclohexyl)aminothiocarbonylamino]-2(5H)-furanone; [0190]
  • rr) 4-[N-(2-pyridinyl)aminothiocarbonylamino]-2(5H)-furanone; [0191]
  • ss) 4-[N-(1-isoquinolinyl)aminothiocarbonylamino]-2(5H)-furanone; [0192]
  • tt) 4-[N-(3-quinolinyl)aminothiocarbonylamino]-2(5H)-furanone; [0193]
  • uu) 4-[N-(3-indolyl)aminothiocarbonylamino]-2(5H)-furanone; [0194]
  • vv) 4-[N-(2-thienyl)aminothiocarbonylamino]-2(5H)-furanone. [0195]
    • EXAMPLE 7 4-(4′-cyanomethylphenylureido)-2(5H)-furanone
  • In a flask equipped with a Dean-Stark apparatus, a mixture of N-(4cyano-methyl)phenylurea (240 mg) and tetronic acid (140 mg) in toluene (3 ml) is heated at reflux for one hour. After cooling to room temperature the solid is filtered off and suspended in boiling absolute ethanol (5 ml) for 30′. [0196]
  • After 2 hours at 20° C. the solid is recovered by filtration and recrystallized from methanol (5 ml), to give 190 mg of product. [0197]
    m.p. 239° C.
    E.A. found % C 60.56 (60.7); H 4.28 (4.31); N 16.22 (16.33).
    (calculated %)
    1H-NMR 3.9 (s, 2H), 5.1 (s, 2H); 5.6 (s, 1H); 7.4 (dd, 4H);
    (DMSO-d6; δ) 9.2 (s, 1H); 9.8 (s, 1H)
    • EXAMPLE 8 4-(3′,4′,5′-trimethoxyphenylureido)-2(5H)-furanone
  • A mixture of 3,4,5-trimethoxyphenylurea (400 mg) and ethyl-4-chloroacetoacetate (350 mg) in dioxane (0.8 ml) is heated at reflux for 4 hours. After one hour at 25° C. the precipitate is recovered by filtration and recrystallized from methanol (3 ml), to give 210 mg of product. [0198]
    m.p. 210-212° C. (with decomposition).
    E.A. found % C 52.91 (52.99), H 5.43 (5.40); N 8.83 (8.74).
    (calculated % for
    C14H16O6N2 ×
    0.5 H2O)
    1H-NMR 3.6 (s, 3H); 3.75 (s, 6H); 5.1 (s, 2H), 5.55
    (DMSO-d6; δ) (s, 1H), 6.7 (s, 2H); 9.1 (s, 1H); 9.8 (s, 1H).
    • EXAMPLE 9 4-[N-(4-ethyl-3-chlorophenyl)aminocarbonylamino]-2(5H)-thiophenone
  • In a flask equipped with a Dean-Stark apparatus 3-chloro-4-ethylphenylurea (338 mg) was suspended in toluene (4 mL), then 4-hydroxy-2-(5H)thiophenone was added together with a catalytic amount of p-toluenesulfonic acid (3 mg). The resultant mixture was refluxed for about three hours then it was cooled at 60° C. and the precipitated solid filtered off. [0199]
  • The so obtained crude material was purified by column chromatography (SiO[0200] 2, eluent CH2Cl2/AcOEt 1:1) to yield pure 4-(3′-chloro-4′-ethylphenylureido)-(5H)-2-thiophenone (98 mg).
    m.p. 244-245° C.
    E.A. found % C 52.3 (52.61); H 4.39 (4.42); N 9.29 (9.44);
    (calculated %) Cl 11.74 (11.95); S 10.87 (10.80)
    1H-NMR 1.1 (t, 3H, CH3—); 2.65 (q, 2H, CH2-Ph); 4.4
    (DMSO-d6; δ) (s, 2H, CH2—S); 6.3 (s, 1H, ═CH—CO); 7.25 (bs, 2H,
    Ph); 7.65 (bs, 1H, Ph); 9.15 (s, 1H, NH-Ph); 9.75
    (s, 1H, NH—C═)
  • Analogously the following compounds are prepared: [0201]
  • a) 4-[(phenyl)aminocarbonylamino]-2(5H)-thiophenone [0202]
    m.p. 216-219° C.
    E.A. found % C 57.3 (56.39); H 4.29 (4.30); N 10.93
    (calculated %) (11.96); S 14.47 (13.69)
    1H-NMR 4.3 (s, 2H, CH2—S); 6.3 (s, 1H, ═CH—CO);
    (DMSO-d6; δ) 7.05 (t, 1H, Ph); 7.3 (t, 2H, Ph); 7.4 (d, 2H,
    Ph); 9.05 (s, 1H, NH-Ph); 9.7 (s, 1H, NH—
    C═)
  • b) 4-[(4-chlorophenyl)aminocarbonylamino]-2(5H)-thiophenone [0203]
    m.p. 258-260° C.
    E.A. found % C 49.09 (49.17); H 3.25 (3.38); N 10.4
    (calculated %) (10.42); Cl 13.2 (13.19); S 11.87 (11.93)
    1H-NMR 4.3 (s, 2H, CH2—S); 6.3 (s, 1H, ═CH—CO); 7.4
    (DMSO-d6; ?) (dd, 4H, Ph): 9.2 (s, 1H, NH-Ph); 9.7 (s, 1H,
    NH—C═)
    • EXAMPLE 10
  • According to the methods described in the previous examples, the following thiophenone derivatives are prepared: [0204]
  • a) 4-[N-(4-fluorophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0205]
  • b) 4-[N-(4-bromophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0206]
  • c) 4-[N-(4-chloro-3-ethylphenyl)aminocarbonylamino]-2(5H)-thiophenone; [0207]
  • d) 4-[N-(4-methylphenyl)aminocarbonylamino]-2(5 H)-thiophenone; [0208]
  • e) 4-[N-(3-chlorophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0209]
  • f) 4-[N-(3-bromophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0210]
  • g) 4-[N-(3-trifluoromethylphenyl)aminocarbonylamino]-2(5H)-thiophenone; [0211]
  • h) 4-[N-(3-methoxyphenyl)aminocarbonylamino]-2(5H)-thiophenone; [0212]
  • i) 4-[N-(3-carboxyphenyl)aminocarbonylamino]-2(5H)-thiophenone; [0213]
  • j) 4-[N-(3-chloro-4-methylphenyl)aminocarbonylamino]-2(5H)-thiophenone; [0214]
  • k) 4-[N-(3,4-dichlorophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0215]
  • l) 4-[N-(3-chloro-4-trifluoromethylphenyl)aminocarbonylamino]-2(5H)-thiophenone; [0216]
  • m) 4-[N-(2-bromophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0217]
  • n) 4-[N-(2-methylphenyl)aminocarbonylamino]-2(5H)-thiophenone [0218]
  • o) 4-[N-(4-aminosulphonylphenyl)aminocarbonylamino]-(5H)-thiophenone; [0219]
  • p) 4-[N-(4-methansulphonylamidophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0220]
  • q) 4-[N-(4-tolylsulphonamidophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0221]
  • r) 4-[N-(2-fluorophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0222]
  • s) 4-[N-(2,4-difluorophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0223]
  • t) 4-[N-(4-ethyl-2-chlorophenyl)aminocarbonylamino]-2(5H)-thiophenone; [0224]
  • u) 4-[N-(isopropyl)aminocarbonylamino]-2(5H)-thiophenone; [0225]
  • v) 4-[N-(cyclopropyl)aminocarbonylamino]-2(5H)-thiophenone; [0226]
  • w) 4-[N-(2-pyridinyl)aminocarbonylamino]-2(5H)-thiophenone; [0227]
  • x) 4-[N-(1-isoquinolinyl)aminocarbonylamino]-2(5H)-thiophenone; [0228]
  • y) 4-[N-(3-quinolinyl)aminocarbonylamino]-2(5H)-thiophenone; [0229]
  • z) 4-[N-(3-indolyl)aminocarbonylamino]-2(5H)-thiophenone; [0230]
  • aa) 4-[N-(2-thienyl)aminocarbonylamino]-2(5H)-thiophenone; [0231]
  • bb) 4-[N-(2-pyrrolidinylaminocarbonylamino]-2(5H)-thiophenone; [0232]
  • cc) 4-[N-(2-furanyl)aminocarbonylamino]-2(5H)-thiophenone; [0233]
  • dd) 4-[N-(4-ethyl-3-chlorophenyl)aminocarbonylamino]-3-methyl-2(5H)-thiophenone; [0234]
  • ee) 4-[N-(4-ethyl-3-chlorophenyl)aminocarbonylamino]-3,5-dimethyl-2(5H)-thiophenone; [0235]
  • ff) 4-[N-(4-ethyl-3-chlorophenyl)aminocarbonylamino]-5-methyl-2(5H)-thiophenone; [0236]
  • gg) 4-N-(4-chlorophenyl)aminocarbonylamino]-3-ethyl-2(5H)-thiophenone; [0237]
  • hh) 4-[N-(4-chlorophenyl)aminocarbonylamino]-5-propyl-2(5H)-thiophenone. [0238]
  • ii) 4-[N-(4-ethyl-3-chlorophenyl)aminothiocarbonylamino]-2(5H)-thiophenone; [0239]
  • jj) 4-[N-(4-chlorophenyl)aminothiocarbonylamino]-2(5H)-thiophenone; [0240]
  • kk) 4-[N-(4-fluorophenyl)aminothiocarbonylamino]-2-(5H)-thiophenone: [0241]
  • ll) 4-[N-(4-chloro-3-ethylphenyl)aminothiocarbonylamino]-2(5H)-thiophenone; [0242]

Claims (8)

1. Compounds of the general formula (I):
Figure US20020058694A1-20020516-C00009
wherein:
A is oxygen or sulfur;
X is oxygen or sulfur;
R1 and R2 are independently hydrogen or an alkyl group with from 1 to 6 carbon atoms;
R is selected from: (C1-C10)alkyl, (C3-C7)cycloalkyl, (C1-C4)alkylthio, (C1-C4)alkylsulphinyl, (C1-C4)alkylsulphonyl, (C1-C4)hydroxyalkyl, naphthyl, phenyl, phenyl substituted by from 1 to 3 groups selected from: (C1-C4)alkyl; chlorine, bromine, iodine or fluorine; (C1-C4)perfluoroalkyl; hydroxy; (C1-C4)alkoxy; amino; mono- or di-(C1-C4)alkylamino; aminosulphonyl; (C1-C4)alkylsulphonamido: phenyl- or tolyl-sulphonamido; carboxy; (C1-C4)alkoxycarbonyl; amidocarbonyl or (C1-C4)alkylamidocarbonyl; carboxaldehyde; (C1-C4)alkylcarbonyl; nitro; phenylthio; cyanomethyl, and optionally substituted phenyloxy or optionally substituted phenyl-(C1-C4)-alkyl or R is a 5- or 6-membered aromatic or non-aromatic heterocycle containing from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, which can be optionally benzocondensed,
the pure stereoisomers or mixtures thereof as well as salts thereof with pharmaceutically acceptable acids or bases, with the proviso, that when A is oxygen and X is oxygen, R is not (C1-C10) alkyl, for the use as medicaments.
2. The compounds of claim 1 for the use as antitumor agents.
3. Compounds of the general formula (I):
Figure US20020058694A1-20020516-C00010
wherein:
A is oxygen or sulfur;
X is oxygen or sulfur;
R1 and R2 are independently hydrogen or an alkyl group with from 1 to 6 carbon atoms;
R is selected from: (C1-C10)alkyl, (C3-C7)cycloalkyl, (C1-C4)alkylthio, (C1-C4)alkylsulphinyl, (C1-C4)alkylsulphonyl, (C1-C4)hydroxyalkyl, naphthyl, phenyl, phenyl substituted by from 1 to 3 groups selected from: (C1-C4)alkyl; chlorine, bromine, iodine or fluorine; (C1-C4)perfluoroalkyl; hydroxy; (C1-C4)alkoxy; amino; mono- or di-(C1-C4)alkylamino; aminosulphonyl; (C1-C4)alkylsulphonamido; phenyl- or tolyl-sulphonamido; carboxy; (C1-C4)alkoxycarbonyl; amidocarbonyl or (C1-C4)alkylamidocarbonyl; carboxaldehyde; (C1-C4)alkylcarbonyl; nitro; phenylthio; cyanomethyl, and optionally substituted phenyloxy or optionally substituted phenyl-(C1-C4)-alkyl or R is a 5- or 6-membered aromatic or non-aromatic heterocycle containing from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, which can be optionally benzocondensed,
the pure stereoisomers or mixtures thereof as well as salts thereof with pharmaceutically acceptable acids or bases, with the proviso that, when A is oxygen and X is oxygen, R is not unsubstituted phenyl or (C1-C10) alkyl.
4. Compounds according to claim 3, in which X is oxygen, R1 and R2 are hydrogen and R is a substituted phenyl group.
5. Compounds according to claim 4, wherein said compounds are:
4-[N-(4-chlorophenyl)aminocarbonylamino]-2(5H)-furanone;
4-[N-(4-ethyl-3-chlorophenyl)aminocarbonylamino]-2(5H)-furanone.
6. Pharmaceutical compositions containing a pharmaceutically effective amount of one or more compounds of formula (I) as depicted in claim 1, in admixture with pharmaceutically acceptable eccipients.
7. The use of the compounds of formula (I) as depicted in claim 1 for the preparation of a medicament having antitumor activity.
8. A process for the preparation of the compounds according to claims 1 to 5, which comprises reacting a compound of formula (VII),
Figure US20020058694A1-20020516-C00011
wherein A is oxygen or sulfur and R1 and R2 have the meanings mentioned above, with an urea or thiourea of formula (III):
Figure US20020058694A1-20020516-C00012
in which R and X have the meanings mentioned above, in a solvent at reflux.
US09/986,310 1997-09-05 2001-11-08 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents Abandoned US20020058694A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/986,310 US20020058694A1 (en) 1997-09-05 2001-11-08 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97115391 1997-09-05
EP97115391.1 1997-09-05
US09/485,709 US6333346B1 (en) 1997-09-05 1998-09-01 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents
US09/986,310 US20020058694A1 (en) 1997-09-05 2001-11-08 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/485,709 Division US6333346B1 (en) 1997-09-05 1998-09-01 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents
PCT/EP1998/005524 Division WO1999012917A1 (en) 1997-09-05 1998-09-01 Ureido and thioureido derivatives of 4-amino-2(5h)-furanones and 4-amino-2(5h)-thiophenones as antitumor agents

Publications (1)

Publication Number Publication Date
US20020058694A1 true US20020058694A1 (en) 2002-05-16

Family

ID=8227318

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/485,709 Expired - Fee Related US6333346B1 (en) 1997-09-05 1998-09-01 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents
US09/986,310 Abandoned US20020058694A1 (en) 1997-09-05 2001-11-08 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/485,709 Expired - Fee Related US6333346B1 (en) 1997-09-05 1998-09-01 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents

Country Status (16)

Country Link
US (2) US6333346B1 (en)
EP (1) EP1009747A1 (en)
JP (1) JP2001515894A (en)
KR (1) KR20010023549A (en)
CN (1) CN1278256A (en)
AR (1) AR014908A1 (en)
AU (1) AU748490B2 (en)
BR (1) BR9812629A (en)
CA (1) CA2302284A1 (en)
CO (1) CO4970714A1 (en)
HR (1) HRP980480A2 (en)
MA (1) MA24668A1 (en)
PE (1) PE107599A1 (en)
TR (1) TR200000589T2 (en)
WO (1) WO1999012917A1 (en)
ZA (1) ZA988096B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1309593B1 (en) * 1999-03-05 2002-01-24 Novuspharma Spa HETEROCYCLIC COMPOUNDS WITH ANTI-TUMOR ACTIVITY.
KR20010094519A (en) * 2000-03-31 2001-11-01 서경배 Synthetic Method of 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives
GB9928696D0 (en) 1999-12-03 2000-02-02 Swan Thomas & Co Ltd Optical devices and methods of manufacture thereof
IT1315267B1 (en) 1999-12-23 2003-02-03 Novuspharma Spa DERIVATIVES OF 2- (1H-INDOL-3-IL) -2-OXO-ACETAMIDES FOR ANTI-TUMOR ACTIVITY
US20060211759A1 (en) * 2001-07-26 2006-09-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Bis-heterocyclic compounds with antitumour and chemosensitising activity
WO2003018575A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
AU2003265267B2 (en) * 2002-07-09 2010-03-11 Fasgen, Llc Novel compounds, pharmaceutical compositions containing same, and methods of use for same
KR20040018295A (en) * 2002-08-22 2004-03-03 임철부 Thioureido ceramide derivatives having potent anti-cancer activity and the pharmaceutical compositions containing the same
KR100555655B1 (en) * 2002-11-20 2006-03-03 임철부 Ureido or thioureido derivatives having anticancer activity and pharmaceutical compositions containing the compound
CN1301253C (en) * 2003-07-31 2007-02-21 中国人民解放军军事医学科学院毒物药物研究所 Five-membered sulfur heterocyclic compound and its use in the preparation of medicines for treating and preventing obesity-related diseases
CN101161645B (en) * 2007-11-27 2010-06-23 南京大学 Urea derivatives and their preparation method and use
CN101560175B (en) * 2009-05-08 2012-10-10 南京大学 Thiourea derivatives and preparation method and use thereof
CN106800544B (en) * 2017-01-19 2019-09-06 华南师范大学 3-halo-4-benzidine-2(5H)-furanone compounds and their application in the preparation of antitumor drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE27894E (en) 1972-05-15 1974-01-22 Hydroxy-j-(j-phenylureido)crotonic acid, gamma lactone compounds
AR206143A1 (en) * 1974-04-17 1976-06-30 Du Pont PROCEDURE FOR THE PREPARATION OF 1 - T - ALKYL - 3 - (2,5 - DIHYDRO - 5 - OXO - 3 - FURYL) UREAS COMPOUNDS
SE7702004L (en) * 1976-03-24 1977-09-25 Du Pont ANTIHYPERTENSIVE FURYL CARBAMIDS
JPS63174983A (en) * 1987-01-16 1988-07-19 Sumitomo Chem Co Ltd Aminobutenolide derivative, production thereof and herbicide comprising said derivative as active ingredient

Also Published As

Publication number Publication date
HRP980480A2 (en) 1999-06-30
MA24668A1 (en) 1999-07-01
ZA988096B (en) 2000-03-22
CN1278256A (en) 2000-12-27
AU9535098A (en) 1999-03-29
CA2302284A1 (en) 1999-03-18
KR20010023549A (en) 2001-03-26
PE107599A1 (en) 1999-11-03
TR200000589T2 (en) 2000-07-21
WO1999012917A1 (en) 1999-03-18
EP1009747A1 (en) 2000-06-21
US6333346B1 (en) 2001-12-25
CO4970714A1 (en) 2000-11-07
AU748490B2 (en) 2002-06-06
JP2001515894A (en) 2001-09-25
BR9812629A (en) 2000-08-22
AR014908A1 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
US6333346B1 (en) Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents
CN108349981B (en) Novel pyrazolo [3, 4-d ] pyrimidine compound or salt thereof
EP0810217A1 (en) Pyrazole derivatives and their pharmaceutical use as smooth muscle cell growth inhibitors
JPWO2006001318A1 (en) Sulfonamide compound
KR870001027B1 (en) Method for preparing carboxyimide derivative
WO1999000381A1 (en) Bis-indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them
US4695567A (en) Pyrrolobenzimidazoles, pharmaceutical compositions containing them and method of using them to treat certain heart and circulatory diseases
US20040009993A1 (en) Pyridopyrimidinones derivatives as telomerase inhibitors
EP0327986A2 (en) Medicaments containing lactams, substituted lactams and process for their preparation
ES2401578T3 (en) Pyridinylacetonitriles
CN112538038B (en) 2-indolone ERR alpha inverse agonist and pharmaceutical composition and application thereof
BE897247A (en) NEW HETEROCYCLIC COMPOUNDS
JPS60158190A (en) Hydantoin derivative, its preparation, and drug containing it
MXPA00002152A (en) Ureido and thioureido derivatives of 4-amino-2(5h)-furanones and 4-amino-2(5h)-thiophenones as antitumor agents
US5043348A (en) Pyrrolealdehydes, their preparation and their use
KR101725292B1 (en) Novel Pyrimidine-4-Carboxylic Acid Derivatives Having Anti-tumor Activity
JP3919272B2 (en) Quinazoline compounds
ITMI990456A1 (en) HETEROCYCLIC COMPOUNDS WITH ANTI-TUMOR ACTIVITY
US11827645B2 (en) Spiro-γ-Lactams, and preparation method and use thereof
NL8303965A (en) NEW FOOD DIAMINE AND GUANIDINE DERIVATIVES; METHOD FOR PREPARING THEREOF MEDICINES CONTAINING THEM; METHOD FOR PREPARING SUCH MEDICINES; APPLICATION OF THE COMPOUNDS FOR THE PREPARATION OF MEDICINAL PRODUCTS AND IN MEDICINE.
US20250009742A1 (en) Novel capsid assembly inhibitors
KR880000451B1 (en) Method for preparing carboxyimide derivative
WO1992016529A1 (en) Novel isoindole derivatives and medicaments containing them
DE4311782A1 (en) Indazole derivatives and medicines containing them
WO1995004034A1 (en) (thio)carbimidinic acid derivatives and medicaments containing the same

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE